Plamotamab
Modify Date: 2024-04-06 11:23:47
Plamotamab structure
|
Common Name | Plamotamab | ||
|---|---|---|---|---|
| CAS Number | 2138442-31-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PlamotamabPlamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and resultes in tumor regression in vivo[1][2]. |
| Name | Plamotamab |
|---|
| Description | Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and resultes in tumor regression in vivo[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Plamotamab 在体外诱导人 PBMC 内源性 B 细胞的杀伤和内源性 CD8+ T 细胞的激活，EC50 值为 0.113 nM[2]。 Plamotamab 在体外诱导 T 细胞介导的对 Raji 肿瘤细胞的杀伤，EC50 值为 0.144 nM[2]。 Plamotamab 结合 CD3δ/ε、CD3+ T 细胞、CD4+ T 细胞、CD8+ T 细胞、B 细胞、Raji 细胞，EC50 分别为 2.1 nM、11.78 nM、10.12 nM、200.3 nM 和 134.8 nM[2]。 |
| In Vivo | Plamotamab (0.17 mg/kg；腹腔注射) 在含有 Raji 异种移植物的人 PBMC 移植小鼠模型中引起肿瘤生长抑制[2]。 Plamotamab (0.3 mg/kg；腹腔注射) 导致食蟹猴中细胞因子释放，安全性有待提高[2]。 |
| References |
| No Any Chemical & Physical Properties |